(Q38180762)

30 August 2017

title

PARP inhibitors for anticancer therapy (English)

1 reference

30 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450632%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Nicola Curtin

series ordinal

1

1 reference

30 August 2017

publication date

1 February 2014

1 reference

Biochemical Society Transactions

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450632%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450632%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450632%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

82-88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450632%20AND%20SRC:MED&resulttype=core&format=json

Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Instability and decay of the primary structure of DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Quality control by DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Poly(ADP-ribose): novel functions for an old molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Role of poly(ADP-ribose) formation in DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

PARP inhibition: PARP1 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Therapeutic applications of PARP inhibitors: anticancer therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Integrating genetic approaches into the discovery of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

(ADP-ribose)n participates in DNA excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20130187

21 January 2018

Identifiers

DOI

10.1042/BST20130187

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450632%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference